News

Prof Bodaghi praises the ingenuity at this year's EURETINA Innovation Spotlight (EIS)

Taiji Sakamoto, MD, PhD, spoke about being a board member of EURETINA and his motivations to be a part of the cooperative work that is a hallmark of EURETINA. The interview took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

Lloyd Clark, MD, discusses the evolution and current practices in the treatment of common retinal diseases such as age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.

At EyeCon 2024, Analisa Arosemena, MD, discussed the shift away from traditional topical therapies towards more proactive management techniques, aiming to enhance patient outcomes in glaucoma care.

Enrico Borrelli, MD, FEBO, speaks about opportunities in the retina space

A collaborative model not only enhances the post-cataract experience but also paves the way for a future where refractive outcomes are accessible to all, regardless of the surgeon's specialty.

Three resident eye care providers—Anupam Garg, MD, PhD; Khanh Huang, OD; and Shail Patel, MD—were honored with the Visionary in Eye Care award at EyeCon 2024, which recognizes their achievements and contributions during their residency programs.

Adam S. Wenick, MD, PhD, discussed myopia interventions across the lifespan at EyeCon 2024, covering treatments, complications, and prevention strategies.

Adam S. Wenick, MD, PhD, chaired a symposium on geographic atrophy (GA) at EyeCon 2024, focusing on the diagnosis, monitoring, and FDA-approved treatments for GA. The session with Leonard Messner, OD, FAAO, also included case presentations that highlighted key factors for clinicians to consider when selecting appropriate treatment options.

In a study, a team of Chinese researchers looked at the mechanisms behind the development of EI and explored effective treatment options.

Srinivas R. Sadda, MD, spoke about the EURETINA meeting, his presentation on ultra widefield imaging, and the value of the international community of retina clinicians connecting in person at meetings. The interview took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

Optometry cochairs Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, OD, MA, FAAO, highlight the conference’s focus on collaboration, featuring topics like red flags for patient care, thyroid eye disease, and diabetes management.

The general secretary of the European Society of Retina Specialists (EURETINA) says the future of AI is here

Brepocitinib is a potential first-in-class dual selective inhibitor of TYK2 and JAK1.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

Peter J. McDonnell, MD, and Laura M. Periman, MD, discuss recent innovations in ophthalmology, emphasizing ocular surface disease and the growing complexity of care at EyeCon 2024, held September 27 and 28, in Fort Lauderdale, Florida.

Neltependocel has received both regulatory and reimbursement approval in Japan

Wendy Lee, MD, sat down with Ophthalmology Times to discuss a symposium she participated in at Eyecon 2024 focusing on Thyroid Eye Disease.

Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab

The NIH-supported findings could pave the way for genetic testing, clinical trials, and therapy development for these diseases.

Dvey-Aharon is an internationally known AI expert and the inventor of AEYE-DS.

Stefano Mercuri, MD, speaks about his team's August Deutman award-winning research on retinitis pigmentosa and Rho gene mutations

Alexandra Miere, MD, PhD, says oculomics is the next big thing in eye care.

Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab

Carl Awh, MD, FASRS, spoke the value of the international community of retina clinicians connecting at global meetings

Investigadores brasileños preocupados por la aparición de metástasis oculares realizaron un estudio retrospectivo y descubrieron que la frecuencia de metástasis oculares era relativamente baja, según su primer autor Matheus Senna Pereira Ogata, MD.